Corvus Pharmaceuticals (CRVS) to Release Quarterly Earnings on Tuesday

by · The Cerbat Gem

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) is projected to announce its Q3 2025 results after the market closes on Tuesday, November 4th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 4:30 PM ET.

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.03. On average, analysts expect Corvus Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Corvus Pharmaceuticals Trading Up 3.6%

NASDAQ:CRVS opened at $8.04 on Friday. Corvus Pharmaceuticals has a 12 month low of $2.54 and a 12 month high of $10.00. The company has a market cap of $599.06 million, a PE ratio of -7.96 and a beta of 0.57. The company has a 50 day simple moving average of $6.63 and a two-hundred day simple moving average of $4.96.

Hedge Funds Weigh In On Corvus Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Sender Co & Partners Inc. purchased a new position in Corvus Pharmaceuticals during the second quarter valued at approximately $52,000. Bayesian Capital Management LP purchased a new position in shares of Corvus Pharmaceuticals during the 2nd quarter valued at $70,000. The Manufacturers Life Insurance Company purchased a new position in shares of Corvus Pharmaceuticals during the 2nd quarter valued at $76,000. New York State Common Retirement Fund purchased a new position in shares of Corvus Pharmaceuticals during the 2nd quarter valued at $95,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Corvus Pharmaceuticals during the 2nd quarter valued at $115,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on CRVS shares. Mizuho set a $13.00 target price on shares of Corvus Pharmaceuticals in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen lowered shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, October 18th. Finally, Barclays began coverage on shares of Corvus Pharmaceuticals in a research report on Monday, October 13th. They set an “overweight” rating and a $16.00 target price for the company. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Corvus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.25.

Read Our Latest Analysis on Corvus Pharmaceuticals

About Corvus Pharmaceuticals

(Get Free Report)

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.

Featured Stories